Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2022 Sep 13;52(5):625–634. doi: 10.1007/s11055-022-01287-3

Neurological Complications of COVID-19 in the Elderly

A Yu Nikitina 1,✉, A Sh Chimagomedova 1, O S Levin 1
PMCID: PMC9468529  PMID: 36119647

Abstract

SARS-CoV-2 virus is a β-coronavirus and produces a severe viral pneumonia which can be complicated by acute respiratory distress syndrome and multiorgan failure. As knowledge of the new coronavirus infection (COVID-19) increases, it has become known that SARS-CoV-2 has pronounced neurotropism, producing a wide spectrum of neurological complications. This article addresses the characteristics of the neurological complications of COVID-19 in elderly people.

Keywords: COVID-19, coronavirus, SARS-CoV-2, neurological complications, encephalopathy, neurodegenerative diseases

Footnotes

Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 121, No. 10, Iss. 2, pp. 5–15, October, 2021.

References

  • 1.Netland J, Meyerholz DK, Moore S, et al. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J. Virol. 2008;82(15):7264–7275. doi: 10.1128/jvi.00737-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Xu J, Zhong S, Liu J, et al. Detection of severe acute respiratory syndrome coronavirus in the brain: Potential role of the chemokine mig in pathogenesis. Clin. Infect. Dis. 2005;41(8):1089–1096. doi: 10.1086/444461. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Roy D, Tripathy S, Kumar Kar S, et al. Study of knowledge, attitude, anxiety and perceived mental healthcare need in Indian population during COVID-19 pandemic. Asian J. Psychiatr. 2020;51:102083. doi: 10.1016/j.ajp.2020.102083. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Mao L, Jin H, Wang H, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683–690. doi: 10.1001/jamaneurol.2020.1127. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Bosso M, Thanaraj TA, Abu-Farha M, et al. The two faces of ACE2: the role of ACE2 receptor and its polymorphisms in hypertension and COVID-19. Mol. Ther. Methods Clin. Dev. 2020;45:56–61. doi: 10.1016/j.omtm.2020.06.017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Varga Z, Flammer AF, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417–1418. doi: 10.1016/S0140-6736(20)30937-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.A. Achar and C. Ghosh, “COVID-19-associated neurological disorders: The potential route of CNS invasion and blood–brain barrier relevance,” Cells, 9, No. 11, 2360 (2020), 10.3390/cells9112360. [DOI] [PMC free article] [PubMed]
  • 8.Lee KW, Khan AHKY, Ching SM, et al. Stroke and novel coronavirus infection in humans: A systematic review and metaanalysis. Front. Neurol. 2020;11:45–51. doi: 10.3389/fneur.2020.579070. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Gkrouzman E, Barbhaiya M, Erkan D, Lockshin MD. Reality check on antiphospholipid antibodies in COVID-19-associated coagulopathy. Arthritis Rheumatol. 2021;73(1):173–174. doi: 10.1002/art.41472. [DOI] [PubMed] [Google Scholar]
  • 10.Bowles L, Platton S, Yartey N, et al. lupus anticoagulant and abnormal coagulation tests in patients with Covid-19. N. Engl. J. Med. 2020;383(3):288–290. doi: 10.1056/NEJMc2013656. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.de Oliveira RMF, de Souza Aguiar PHC, de Paula RWRM, et al. Stroke in patients infected by the novel coronavirus and its causal mechanisms: A narrative review. J. Am. Coll. Emerg. Physicians Open. 2020;5:34–39. doi: 10.1002/emp2.12332. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Ritchie K, Chan D. The emergence of cognitive COVID. World Psychiatry. 2021;20(1):52–53. doi: 10.1002/wps.20837. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Alexopoulos H, Magira E, Bitzogli K, et al. Anti-SARS-CoV-2 antibodies, blood–brain barrier dysfunction, and neurological outcome studies in 8 stuporous and comatose patients. Neurol. Neuroimmunol. Neuroinfl amm. 2020;7:e893. doi: 10.1212/NXI.0000000000000893. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Rege S. COVID-19 and the Brain – Pathogenesis and Neuropsychiatric Manifestations of SARS-CoV-2 CNS Involvemen. FRANZCP: MRCPsych; 2020. [Google Scholar]
  • 15.Qureshi AI, Abd-Allah F, Al-Senani F, et al. Management of acute ischemic stroke in patients with COVID-19 infection: Report of an international panel. Int. J. Stroke. 2020;15(5):540–554. doi: 10.1177/1747493020923234. [DOI] [PubMed] [Google Scholar]
  • 16.Dries DJ, Hussein HM. Coronavirus disease 2019 and stroke. Air Med. J. 2021;45:56–61. doi: 10.1016/j.amj.2020.12.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Zheng Z, Peng F, Xu B, et al. Risk factors of critical and mortal COVID-19 cases: A systematic literature review and meta-analysis. J. Infect. 2020;81(2):E16–E25. doi: 10.1016/j.jinf.2020.04.021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.D. V. Jillella, N. J. Janocko, F. Nahab, et al., “Ischemic stroke in COVID-19: An urgent need for early identifi cation and management,” PLoS One, 15, No. 9, e0239443 (2020), 10.1371/journal.pone.0239443. [DOI] [PMC free article] [PubMed]
  • 19.Yaghi S, Ishida K, Torres J, et al. SARS-CoV-2 and stroke in a New York healthcare system. Stroke. 2020;51(7):2002–2011. doi: 10.1161/STROKEAHA.120.030335. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.S. Kihira, J. Schefflein, K. Mahmoudi, et al., “Association of coronavirus disease (COVID-19) with large vessel occlusion strokes: a case-control study,” Am. J. Roentgenol., 216, No. 1, 150–156 (2021), 10.2214/AJR.20.23847. [DOI] [PubMed]
  • 21.Beyrouti R, Adams ME, Benjamin L, et al. Characteristics of ischaemic stroke associated with COVID-19. J. Neurol. Neurosurg. Psychiatry. 2020;91(8):889–891. doi: 10.1136/jnnp-2020-323586. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Ntaios G, Michel P, Georgiopoulos G, et al. Characteristics and outcomes in patients with COVID-19 and acute ischemic stroke: the Global COVID-19 Stroke Registry. Stroke. 2020;51(9):254–258. doi: 10.1161/STROKEAHA.120.031208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Iadecola C, Anrather J, Kamel H. Effects of COVID-19 on the nervous system. Cell. 2020;23:45–49. doi: 10.1016/j.cell.2020.08.028. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Mishra AK, Sahu KK, Lal A, Sargent J. Patterns of heart injury in COVID-19 and relation to outcome. J. Med. Virol. 2020;92(10):1747–1747. doi: 10.1002/jmv.25847. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Peng K-P. Association between COVID-19 and headache: What evidence and history tell us. Cephalalgia. 2020;40(13):1403–1405. doi: 10.1177/0333102420965969. [DOI] [PubMed] [Google Scholar]
  • 26.Spence JD, De Freitas GR, Pettigrew LC, et al. Mechanisms of stroke in COVID-19. Cerebrovasc. Dis. 2020;49(4):451–458. doi: 10.1159/000509581. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.J. Kwan, M. Brown, P. Bentley, et al., “Impact of COVID-19 pandemic on a regional stroke thrombectomy service in the United Kingdom,” Cerebrovasc. Dis., 24, 1–7 (2020), 10. 1159/000512603. [DOI] [PMC free article] [PubMed]
  • 28.Thachil J. The versatile heparin in COVID-19. J. Thromb. Haemost. 2020;18(5):1020–1022. doi: 10.1111/jth.14821. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.H.-C. Diener, P. Berlit, and J. Masjuan, “COVID-19: patients with stroke or risk of stroke,” Eur. Heart J. Suppl., 22, Suppl. P, 25–28 (2020), 10.1093/eurheartj/suaa174. [DOI] [PMC free article] [PubMed]
  • 30.Benger M, Williams O, Siddiqui J, Sztriha L. Intracerebral haemorrhage (ICH) and COVID-19: Clinical characteristics from a case series. Brain Behav. Immun. 2020;5:23–29. doi: 10.1016/j.bbi.2020.06.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.J. Nawabi, A. Morotti, M. Wildgruber, et al., “Clinical and imaging characteristics in patients with SARS-CoV-2 infection and acute intracranial hemorrhage,” J. Clin. Med., 9, No. 8, 2543 (2020), 10.3390/jcm9082543. [DOI] [PMC free article] [PubMed]
  • 32.J. Rogg, A. Baker, and G. Tung, “Posterior reversible encephalopathy syndrome (PRES, Another Imaging manifestation of COVID-19,” Interdiscip. Neurosurg., 22, 100808 (2020), 10.1016/j.inat.2020.100808. [DOI] [PMC free article] [PubMed]
  • 33.Franceschi AM, Ahmed O, Giliberto L, Castillo M. hemorrhagic posterior reversible encephalopathy syndrome as a manifestation of COVID-19 infection. AJNR Am. J. Neuroradiol. 2020;41(7):1173–1176. doi: 10.3174/ajnr.A6595. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.H.-Y. Wang, X.-L. Li, Z.-R. Yan, et al., “Potential neurological symptoms of COVID-19,” Ther. Adv. Neurol. Disord., 13, 175628 6420917830 (2020), 10.1177/1756286420917830. [DOI] [PMC free article] [PubMed]
  • 35.Y. Alnefeesi, A. Siegel, L. M. W. Lui, et al., “Impact of SARS-CoV-2 infection on cognitive functions: A systematic review,” Front. Psychiatry, 11, 1629 (2020), 10.13140/RG.2.2.14530.40649. [DOI] [PMC free article] [PubMed]
  • 36.Efe IE, Aydin OU, Alabulut A, et al. COVID-19-associated encephalitis mimicking glial tumor. World Neurosurg. 2020;140:46–49. doi: 10.1016/j.wneu.2020.05.194. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Baker HA, Safavynia SA, Evered LA. The ‘third wave’: impending cognitive and functional decline in COVID-19 survivors. Brit. J. Anaesth. 2021;126(1):44–47. doi: 10.1016/j.bja.2020.09.045. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Helms J, Kremer S, Merdji H, et al. Delirium and encephalopathy in severe COVID-19: a cohort analysis of ICU patients. Crit. Care. 2020;24(1):1–11. doi: 10.1186/s13054-020-03200-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Taquet M, Geddes JR, Husain M, et al. 6-Month neurological and psychiatric outcomes in 236,379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8(5):416–427. doi: 10.1016/S2215-0366(21)00084-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Vrillon A, Mhanna E, Aveneau C, et al. COVID-19 in adults with dementia: clinical features and risk factors of mortality – a clinical cohort study on 125 patients. Alzheimers Res. Ther. 2021;13(1):1–8. doi: 10.1186/s13195-021-00820-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Miners S, Kehoe PJ, Love S. Cognitive impact of COVID-19: looking beyond the short term. Alzheimers Res. Ther. 2020;12(1):1–16. doi: 10.1186/s13195-020-00744-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat. Med. 2020;8:1–15. doi: 10.1038/s41591-021-01283-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Seshadri S, De Erausquin GA, Snyder H, et al. The chronic neuropsychiatric sequelae of COVID-19: The need for a prospective study of viral impact on brain functioning. Alzheimers Dement. 2020;17(6):1056–1065. doi: 10.1002/alz.12255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Moriguchi T, Harii N, Goto J, et al. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. Int. J. Infect. Dis. 2020;94:55–58. doi: 10.1016/j.ijid.2020.03.062. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Khodamoradi Z, Hosseini SA, Saadi MHG, et al. COVID-19 meningitis without pulmonary involvement with positive cerebrospinal fluid PCR. Eur. J. Neurol. 2020;27(12):2668–2669. doi: 10.1111/ene.14536. [DOI] [PubMed] [Google Scholar]
  • 46.Tuma RL, Guedes BF, Carra R, et al. Clinical, cerebrospinal fl uid, and neuroimaging fi ndings in COVID-19 encephalopathy: a case series. Neurol. Sci. 2020;42(2):479–489. doi: 10.1007/s10072-020-04946-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Montalvan V, Lee J, Bueso T, et al. Neurological manifestations of COVID-19 and other coronavirus infections: a systematic review. Clin. Neurol. Neurosurg. 2020;194:105921. doi: 10.1016/j.clineuro.2020.105921. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Merello M, Bhatia KP, Obeso JA. SARS-CoV-2 and the risk of Parkinson’s disease: Facts and fantasy. Lancet Neurol. 2021;20(2):94–95. doi: 10.1016/S1474-4422(20)30442-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Pilotto A, Masciocchi S, Volonghi I, et al. SARS-CoV-2 encephalitis is a cytokine release syndrome: Evidences from cerebrospinal fluid analyses. Clin. Infect. Dis. 2021;73(9):e3018–e3026. doi: 10.1093/cid/ciaa1933. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Peng K-P. Association between COVID-19 and headache: What evidence and history tell us. Cephalalgia. 2020;40(13):1403–1405. doi: 10.1177/0333102420965969. [DOI] [PubMed] [Google Scholar]
  • 51.Bobker SM, Robbins MS. Covid-19 and headache: A primer for trainees. Headache. 2020;60(8):1806–1811. doi: 10.1111/head.13884. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.M. Amanat, N. Rezaei, M. Roozbeh, et al., “Neurological manifestations as the predictors of severity and mortality in hospitalized individuals with COVID-19: A multicenter prospective clinical study,” BMC Neurol., 21, No. 1, 116 (2021), 10.21203/rs.3.rs-140606/v1. [DOI] [PMC free article] [PubMed]
  • 53.Tolebeyan AS, Zhang N, Cooper V, Kuruvilla DE. Headache in patients with severe acute respiratory syndrome coronavirus 2 infection: a narrative review. Headache. 2020;60(10):2131–2138. doi: 10.1111/head.13980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Weng L-M, Su X, Wang X-Q. Pain symptoms in patients with coronavirus disease (COVID-19): A literature review. J. Pain Res. 2021;14:147–159. doi: 10.2147/JPR.S269206. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Berger JR. COVID-19 and the nervous system. J. Neurovirol. 2020;26:143–148. doi: 10.1007/s13365-020-00840-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Agyeman AA, Chin KL, Landersdorfer CB, et al. Smell and taste dysfunction in patients with COVID-19: a systematic review and meta-analysis. Mayo Clin. Proc. 2020;95(8):1621–1631. doi: 10.1016/j.mayocp.2020.05.030. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Trubiano JA, Vogrin S, Kwong JC, Homes N. Alterations in smell or taste – classic coronavirus disease 2019? Clin. Infect. Dis. 2020;71(16):2307–2309. doi: 10.1093/cid/ciaa655. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Y. Lee, P. Min, S. Lee, and S.-W. Kim, “Prevalence and duration of acute loss of smell or taste in COVID-19 patients,” J. Korean Med. Sci., 35, No. 18, e174 (2020), 10.3346/jkms.2020.35.e174. [DOI] [PMC free article] [PubMed]
  • 59.Kandemirli SG, Dogan L, Sarikaya ZT, et al. Brain MRI fi ndings in patients in the intensive care unit with COVID-19 infection. Radiology. 2020;297(1):232–235. doi: 10.1148/radiol.2020201697. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Emami A, Fadakar N, Akbari A, et al. Seizure in patients with COVID-19. Neurol. Sci. 2020;41(11):3057–3061. doi: 10.1007/s10072-020-04731-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.M. S. Alshebri, R. A. Alshouimi, N. A. Alhumidi, and A. I. Alshaya, “Neurological complications of SARS-CoV, MERS-CoV, and COVID-19,” SN Compr. Clin. Med., 1–11 (2020), 10.1007/s42399-020-00589-2. [DOI] [PMC free article] [PubMed]
  • 62.Nikbakht F, Mohammadkhanizadeh A, Mohammadi E. How does the COVID-19 cause seizure and epilepsy in patients? The potential mechanisms. Mult. Scler. Relat. Disord. 2020;46:102535. doi: 10.1016/j.msard.2020.102535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.M. C. Rivera, C. Mastronardi, C. T. Silva-Aldana, et al., “Myalgic encephalomyelitis/chronic fatigue syndrome: a comprehensive review,” Diagnostics (Basel), 9, No. 3, 91 (2019), 10.3390/diagnostics9030091. [DOI] [PMC free article] [PubMed]
  • 64.Glassford JAG. The neuroinfl ammatory etiopathology of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) Front. Physiol. 2017;8:88. doi: 10.3389/fphys.2017.00088. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Pietrangelo T, Fulle S, Coscia F, et al. Old muscle in young body: an aphorism describing the chronic fatigue syndrome. Eur. J. Transl. Myol. 2018;28(3):56–61. doi: 10.4081/ejtm.2018.7688. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Islam MF, Cotler J, Jason LA. Post-viral fatigue and COVID-19: lessons from past epidemics. Fatigue Biomed. Health Behav. 2020;8(2):61–69. doi: 10.1080/21641846.2020.1778227. [DOI] [Google Scholar]
  • 67.Moldofsky H, Patcai J. Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study. BMC Neurol. 2011;11(1):1–7. doi: 10.1186/1471-2377-11-37. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.S. H. Lee, H.-S. Shin, H. Y. Park, et al., “Depression as a mediator of chronic fatigue and post-traumatic stress symptoms in middle east respiratory syndrome survivors,” Psychiatry Investig., 16, No. 1, 59 (2019), 10.30773/pi.2018.10.22.3. [DOI] [PMC free article] [PubMed]
  • 69.Wostyn P. COVID-19 and chronic fatigue syndrome: Is the worst yet to come? Med. Hypotheses. 2021;146:110469. doi: 10.1016/j.mehy.2020.110469. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Morris G, Maes M, Berk M, Puri BK. Myalgic encephalomyelitis or chronic fatigue syndrome: how could the illness develop? Metab. Brain. Dis. 2019;34(2):385–415. doi: 10.1007/s11011-019-0388-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.L. J. Robinson, P. Gallagher, S. Watson, et al., “Impairments in cognitive performance in chronic fatigue syndrome are common, not related to co-morbid depression but do associate with autonomic dysfunction,” PLoS One, 14, No. 2, e0210394 (2019), 10.1371/journal.pone.0210394. [DOI] [PMC free article] [PubMed]
  • 72.Mueller C, Lin JC, Sheriff S, et al. Evidence of widespread metabolite abnormalities in myalgic encephalomyelitis/chronic fatigue syndrome: assessment with whole-brain magnetic resonance spectroscopy. Brain Imaging Behav. 2020;14(2):562–572. doi: 10.1007/s11682-018-0029-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.O. Rasouli, M. E. Gotaas, A.-K. Stensdotter, et al., “Neuropsychological dysfunction in chronic fatigue syndrome and the relation between objective and subjective fi ndings,” Neuropsychology, 33, No. 5, 658 (2019), 10.1037/neu0000550. [DOI] [PubMed]
  • 74.Vian J, Pereira C, Chavarria V, et al. The renin-angiotensin system: a possible new target for depression. BMC Medicine. 2017;15(1):1–13. doi: 10.1186/s12916-017-0916-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Fazzini E, Fleming J, Fahn S. Cerebrospinal fl uid antibodies to coronavirus in patients with Parkinson’s disease. Mov. Disord. 1992;7(2):153–158. doi: 10.1002/mds.870070210. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Camacho-Soto A, Faust I, Racette BA, et al. Herpesvirus infections and risk of Parkinson’s disease. Neurodegener. Dis. 2020;20:97–103. doi: 10.1159/000512874. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.H. Wang, X. Liu, C. Tan, et al., “Bacterial, viral, and fungal infection-related risk of Parkinson’s disease: Meta-analysis of cohort and case-control studies,” Brain Behav., 10, No. 3, e01549 (2020), 10.1002/brb3.1549. [DOI] [PMC free article] [PubMed]
  • 78.Dolatshahi M, Sabahi M, Aarabi MH. Pathophysiological clues to how the emergent SARS-CoV-2 can potentially increase the susceptibility to neurodegeneration. Mol. Neurobiol. 2021;58(5):2379–2394. doi: 10.1007/s12035-020-02236-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.D. Tejera, D. Mercan, J. M. Sanchez-Caro, et al., “Systemic inflammation impairs microglial Aβ clearance through NLRP 3 Inflammasome,” EMBO J., 38, No. 17, e101064 (2019), 10.15252/embj.2018101064. [DOI] [PMC free article] [PubMed]
  • 80.D. S. A. Simpson and P. L. Oliver, “ROS generation in microglia: Understanding oxidative stress and inflammation in neurodegenerative disease,” Antioxidants, 9, No. 8, 743 (2020), 10.3390/antiox9080743. [DOI] [PMC free article] [PubMed]
  • 81.Abiodun OA, Ola MS. Role of brain renin angiotensin system in neurodegeneration: An update. Saudi J. Biol. Sci. 2020;27(3):905–912. doi: 10.1016/j.sjbs.2020.01.026. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.G. E. Ivanova, E. V. Mel’nikova, O. S. Levin, et al., “Current challenges in the rehabilitation of stroke patients on the bk of the new coronavirus infection (COVID-19). Resolution of the Council of Experts,” Zh. Nevrol. Psikhiatr., 120, No. 8, part 2, 81–87 (2020), 10.17116/jnevro202012008281. [DOI] [PubMed]
  • 83.Alvarez XA. Cerebrolysin reduces microglial activation in vivo and in vitro: a potential mechanism of neuro-protection. J. Neural. Transm. Suppl. 2000;59:81–292. doi: 10.1007/978-3-7091-6781-6_30. [DOI] [PubMed] [Google Scholar]
  • 84.Yanlu Z, Chopp M. Improvement in functional recovery with administration of Cerebrolysin after experimental closed head injury. J. Neurosurg. 2013;118:67–72. doi: 10.3171/2013.3.JNS122061. [DOI] [PubMed] [Google Scholar]
  • 85.Malashenkova IK, Gavrilova SI. Impact of cerebrolysin therapy on neuropsychological state, oxygen transporting function of the blood and systemic infl ammation markers in patients with amnestic mild cognitive impairment. J. Policlin. Neurol. Rheumatol. 2017;4:34–41. [Google Scholar]
  • 86.B. Hutter-Paier, E. Grygar, and M. Windisch, “Death of cultured telencephalon neurons induced by glutamate is reduced by the peptide derivative Cerebrolysin, J. Neural Transm., 47, 267–273 (1996). [DOI] [PubMed]
  • 87.Li Z. Sonic hedgehog signaling pathway mediates Cerebrolysinimproved neurological function after stroke. Stroke. 2013;44:51–56. doi: 10.1161/STROKEAHA.111.000831. [DOI] [PubMed] [Google Scholar]
  • 88.Rockenstein E. Effects of Cerebrolysin on neurogenesis in an APP transgenic model of Alzheimer’s disease. Acta Neuropathol. 2007;113:265–262. doi: 10.1007/s00401-006-0166-5. [DOI] [PubMed] [Google Scholar]
  • 89.Heiss WD. Cerebrolysin in patients with acute ischemic stroke in Asia. Results of a double-blind, placebo-controlled randomized trial. Stroke. 2012;43:45–51. doi: 10.1161/STROKEAHA.111.628537. [DOI] [PubMed] [Google Scholar]
  • 90.Chang H. Cerebrolysin combined with rehabilitation promotes motor recovery in patients with severe motor impairment after stroke. BMC Neurol. 2016;34:45–50. doi: 10.1186/s12883-016-0553-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 91.Muresanu DF. Cerebrolysin and recovery after stroke (CARS) Stroke. 2016;47:151–159. doi: 10.1161/STROKEAHA.115.009416. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 92.Guekht A, et al. Cerebrolysin in vascular dementia: Improvement of clinical outcome in a randomized, double blind, placebo-controlled multicenter trial. J. Stroke Cerebrovasc. Dis. 2011;20(4):310–318. doi: 10.1016/j.jstrokecerebrovasdis.2010.01.012. [DOI] [PubMed] [Google Scholar]
  • 93.Chutko LS, Rozhkova AV, Sidorenko VA, et al. Emotional burnout syndrome: quality of life and pharmacotherapy. Psikhiatr. Psikhofarmakoter. 2012;6:67–71. [Google Scholar]

Articles from Neuroscience and Behavioral Physiology are provided here courtesy of Nature Publishing Group

RESOURCES